Sales & Marketing Sponsored 12 Questions with Pilar de la Rocha Mur Pilar de la Rocha Mur is Head of Clinical Operations EMEA (Europe, Middle East, and Africa) at BeiGene.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.